Here, we analyzed whether the decreased EGFR protein levels obtained via PLK1 inhibition could increase the efficacy of EGFR TKIs (e.g., Osimertinib) in causing cytotoxicity in the EGFR-mutant NSCLC sensitive cell lines PC9 and H1975. The gene discussed is PLK1; the disease is non-small cell lung carcinoma.